Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
TALK vs DBVT vs ALKS vs OPRX vs INVA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Healthcare Information Services
Biotechnology
TALK vs DBVT vs ALKS vs OPRX vs INVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Biotechnology | Medical - Healthcare Information Services | Biotechnology |
| Market Cap | $868M | $1712.35T | $5.90B | $124M | $1.93B |
| Revenue (TTM) | $229M | $0.00 | $1.56B | $109M | $424M |
| Net Income (TTM) | $8M | $-168M | $153M | $5M | $504M |
| Gross Margin | 43.0% | — | 65.4% | 67.3% | 76.2% |
| Operating Margin | 1.4% | — | 12.3% | 10.7% | 14.8% |
| Forward P/E | 38.2x | — | 24.8x | 7.0x | 11.9x |
| Total Debt | $0.00 | $22M | $70M | $5M | $269M |
| Cash & Equiv. | $37M | $194M | $1.12B | $23M | $551M |
TALK vs DBVT vs ALKS vs OPRX vs INVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 20 | May 26 | Return |
|---|---|---|---|
| Talkspace, Inc. (TALK) | 100 | 52.9 | -47.1% |
| DBV Technologies S.… (DBVT) | 100 | 48.6 | -51.4% |
| Alkermes plc (ALKS) | 100 | 196.6 | +96.6% |
| OptimizeRx Corporat… (OPRX) | 100 | 46.9 | -53.1% |
| Innoviva, Inc. (INVA) | 100 | 168.3 | +68.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TALK vs DBVT vs ALKS vs OPRX vs INVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TALK is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
- 22.0% revenue growth vs DBVT's -100.0%
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs OPRX's -30.1%
Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.
OPRX is the clearest fit if your priority is value.
- Lower P/E (7.0x vs 11.9x)
INVA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 0 yrs, beta 0.13
- 94.9% 10Y total return vs ALKS's -11.0%
- Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
- Beta 0.13, current ratio 14.64x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 22.0% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (7.0x vs 11.9x) | |
| Quality / Margins | 118.9% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.13 vs OPRX's 2.28 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs OPRX's -30.1% | |
| Efficiency (ROA) | 32.4% ROA vs DBVT's -89.0% |
TALK vs DBVT vs ALKS vs OPRX vs INVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
TALK vs DBVT vs ALKS vs OPRX vs INVA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
OPRX leads in 2 of 6 categories
INVA leads 1 • TALK leads 1 • DBVT leads 0 • ALKS leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
INVA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to TALK's 3.4%. On growth, TALK holds the edge at +29.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $229M | $0 | $1.6B | $109M | $424M |
| EBITDAEarnings before interest/tax | $7M | -$112M | $212M | $16M | $86M |
| Net IncomeAfter-tax profit | $8M | -$168M | $153M | $5M | $504M |
| Free Cash FlowCash after capex | -$2M | -$151M | $392M | $12M | $181M |
| Gross MarginGross profit ÷ Revenue | +43.0% | — | +65.4% | +67.3% | +76.2% |
| Operating MarginEBIT ÷ Revenue | +1.4% | — | +12.3% | +10.7% | +14.8% |
| Net MarginNet income ÷ Revenue | +3.4% | — | +9.8% | +4.7% | +118.9% |
| FCF MarginFCF ÷ Revenue | -0.9% | — | +25.1% | +10.6% | +42.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.3% | — | +28.2% | -0.2% | +10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +91.5% | -4.1% | — | +4.0% |
Valuation Metrics
OPRX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 6.9x trailing earnings, INVA trades at a 95% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than TALK's 137.8x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $868M | $1712.35T | $5.9B | $124M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $830M | $1712.35T | $4.9B | $105M | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | 129.50x | -0.76x | 24.76x | 24.56x | 6.91x |
| Forward P/EPrice ÷ next-FY EPS est. | 38.20x | — | — | 7.04x | 11.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.67x |
| EV / EBITDAEnterprise value multiple | 137.77x | — | 17.25x | 6.55x | 8.10x |
| Price / SalesMarket cap ÷ Revenue | 3.79x | — | 4.00x | 1.13x | 4.55x |
| Price / BookPrice ÷ Book value/share | 7.69x | 0.66x | 3.28x | 0.98x | 1.65x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | 6.62x | 9.88x |
Profitability & Efficiency
Evenly matched — ALKS and INVA each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. OPRX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to INVA's 0.23x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +6.9% | -130.2% | +8.8% | +4.2% | +46.5% |
| ROA (TTM)Return on assets | +5.9% | -89.0% | +5.4% | +3.0% | +32.4% |
| ROICReturn on invested capital | +3.9% | — | +18.9% | +7.1% | +14.2% |
| ROCEReturn on capital employed | +2.7% | -145.7% | +14.2% | +7.6% | +12.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 8 | 5 |
| Debt / EquityFinancial leverage | — | 0.13x | 0.04x | 0.04x | 0.23x |
| Net DebtTotal debt minus cash | -$37M | -$172M | -$1.0B | -$19M | -$282M |
| Cash & Equiv.Liquid assets | $37M | $194M | $1.1B | $23M | $551M |
| Total DebtShort + long-term debt | $0 | $22M | $70M | $5M | $269M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | 32.30x | 1.26x | 63.45x |
Total Returns (Dividends Reinvested)
TALK leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $1,266 for OPRX. Over the past 12 months, DBVT leads with a +110.4% total return vs OPRX's -30.1%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs OPRX's -23.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +47.6% | +4.9% | +25.3% | -46.6% | +14.7% |
| 1-Year ReturnPast 12 months | +70.4% | +110.4% | +16.5% | -30.1% | +21.7% |
| 3-Year ReturnCumulative with dividends | +490.0% | +19.7% | +14.5% | -54.4% | +95.2% |
| 5-Year ReturnCumulative with dividends | -47.7% | -69.1% | +60.9% | -87.3% | +94.4% |
| 10-Year ReturnCumulative with dividends | -48.7% | -87.0% | -11.0% | +110.5% | +94.9% |
| CAGR (3Y)Annualised 3-year return | +80.7% | +6.2% | +4.6% | -23.0% | +25.0% |
Risk & Volatility
Evenly matched — TALK and INVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs OPRX's 29.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.86x | 1.26x | 1.06x | 2.28x | 0.13x |
| 52-Week HighHighest price in past year | $5.20 | $26.18 | $36.60 | $22.25 | $25.15 |
| 52-Week LowLowest price in past year | $2.22 | $7.53 | $25.17 | $5.54 | $16.52 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +76.3% | +96.7% | +29.8% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 62.7 | 48.1 | 60.2 | 46.9 | 39.9 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 252K | 2.3M | 476K | 621K |
Analyst Outlook
OPRX leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: TALK as "Hold", DBVT as "Buy", ALKS as "Buy", OPRX as "Buy", INVA as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 1.4% for TALK (target: $5).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $5.25 | $46.33 | $44.00 | $17.00 | $37.67 |
| # AnalystsCovering analysts | 10 | 15 | 28 | 15 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.0% | 0.0% | +0.5% | 0.0% | +0.2% |
OPRX leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). INVA leads in 1 (Income & Cash Flow). 2 tied.
TALK vs DBVT vs ALKS vs OPRX vs INVA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TALK or DBVT or ALKS or OPRX or INVA a better buy right now?
For growth investors, Talkspace, Inc.
(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TALK or DBVT or ALKS or OPRX or INVA?
On trailing P/E, Innoviva, Inc.
(INVA) is the cheapest at 6. 9x versus Talkspace, Inc. at 129. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — TALK or DBVT or ALKS or OPRX or INVA?
Over the past 5 years, Innoviva, Inc.
(INVA) delivered a total return of +94. 4%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TALK or DBVT or ALKS or OPRX or INVA?
By beta (market sensitivity over 5 years), Innoviva, Inc.
(INVA) is the lower-risk stock at 0. 13β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 1706% more volatile than INVA relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — TALK or DBVT or ALKS or OPRX or INVA?
By revenue growth (latest reported year), Talkspace, Inc.
(TALK) is pulling ahead at 22. 0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TALK or DBVT or ALKS or OPRX or INVA?
Innoviva, Inc.
(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TALK or DBVT or ALKS or OPRX or INVA more undervalued right now?
On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.
0x forward P/E versus 38. 2x for Talkspace, Inc. — 31. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.
08Which pays a better dividend — TALK or DBVT or ALKS or OPRX or INVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is TALK or DBVT or ALKS or OPRX or INVA better for a retirement portfolio?
For long-horizon retirement investors, Innoviva, Inc.
(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TALK and DBVT and ALKS and OPRX and INVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TALK is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.